ESMO 2019 | IMpower110: atezolizumab vs chemo in PD-L1–selected NSCLC

David Spigel

Here, David Spigel, MD, Sarah Cannon Research Institute, Nashville, TN, provides an interim OS analysis of the Phase III IMpower110 study (NCT02409342) of atezolizumab vs platinum-based chemotherapy as a first-line treatment in PD-L1–selected non-small cell lung cancer (NSCLC). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video